Plain-English translation of NCT07304440 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether AdiaVita (stem cells and related cell products from umbilical cord blood) combined with works better than alone for reducing autism symptoms in children ages 3–12. About 100 children with confirmed autism will be randomly assigned to receive either the medication plus , or just with a placebo infusion. Symptom improvement will be measured over 12 months using standard checklists completed by parents and teachers.
Autism symptoms can be challenging for children and families, and current treatment options are limited. Researchers want to see if this medication might help reduce some autism symptoms by working together with , a natural substance in the body.
You likely qualify if…
You likely don't qualify if…
If you are randomly selected for the active treatment group, your child will receive monthly infusions of the medication plus through an IV for 3 months, along with a topical spray to use twice daily at home. The other group will receive infusions plus a saline placebo for 2 months, with the same daily spray. All families will have regular clinic visits over 12 months to monitor safety and track symptom changes using parent and teacher checklists. If your child is in the -only group and remains healthy, you may have the option to switch to receiving the active medication at no extra cost.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United States